ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SGMT vs WVE // REVENUE GROWTH (YOY)

Sagimet Biosciences Inc. (Series A) (NASDAQ) VS. Wave Life Sciences Inc. (NASDAQ) • 15-METRIC TALLY: SGMT 2 — WVE 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SGMT VS. WVE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SGMT WVE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -6.21% — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) ACTIVE — -60.50% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.85 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 53.2 49.1 +4.09 SGMT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $735.7M $715.9M $19.7M SGMT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SGMT REV WVE REV SGMT GROSS % WVE GROSS % SGMT FCF WVE FCF
FY 2025 $0 $42.7M — — -$45.6M -$188.2M
FY 2024 $0 $108.3M — — -$42.4M -$152.0M
FY 2023 $2.0M $113.3M — — -$23.8M -$19.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SGMT // BETA —
WVE // BETA —